DE60104130D1 - 1-(alkyl), 1-[(heteroaryl)alkyl] und 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-onderivate - Google Patents

1-(alkyl), 1-[(heteroaryl)alkyl] und 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-onderivate

Info

Publication number
DE60104130D1
DE60104130D1 DE60104130T DE60104130T DE60104130D1 DE 60104130 D1 DE60104130 D1 DE 60104130D1 DE 60104130 T DE60104130 T DE 60104130T DE 60104130 T DE60104130 T DE 60104130T DE 60104130 D1 DE60104130 D1 DE 60104130D1
Authority
DE
Germany
Prior art keywords
alkyl
imidazo
pyrimidin
pyridinyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60104130T
Other languages
English (en)
Other versions
DE60104130T2 (de
Inventor
Alistair Lochead
Severine Marguerie
Mourad Saady
Philippe Yaiche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Mitsubishi Pharma Corp filed Critical Sanofi Synthelabo SA
Publication of DE60104130D1 publication Critical patent/DE60104130D1/de
Application granted granted Critical
Publication of DE60104130T2 publication Critical patent/DE60104130T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
DE60104130T 2000-09-01 2001-08-31 1-(alkyl), 1-[(heteroaryl)alkyl] und 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-onderivate Expired - Lifetime DE60104130T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00402411 2000-09-01
EP00402411A EP1184384A1 (de) 2000-09-01 2000-09-01 1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyridin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
PCT/EP2001/010725 WO2002018385A1 (en) 2000-09-01 2001-08-31 1-[ALKYL], 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES

Publications (2)

Publication Number Publication Date
DE60104130D1 true DE60104130D1 (de) 2004-08-05
DE60104130T2 DE60104130T2 (de) 2005-03-10

Family

ID=8173838

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60104130T Expired - Lifetime DE60104130T2 (de) 2000-09-01 2001-08-31 1-(alkyl), 1-[(heteroaryl)alkyl] und 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-onderivate

Country Status (17)

Country Link
US (2) US7067521B2 (de)
EP (2) EP1184384A1 (de)
JP (1) JP4958379B2 (de)
KR (1) KR100775192B1 (de)
CN (1) CN1247584C (de)
AR (1) AR030588A1 (de)
AT (1) ATE270293T1 (de)
AU (2) AU2002212248B2 (de)
CA (1) CA2419875C (de)
DE (1) DE60104130T2 (de)
DK (1) DK1315730T3 (de)
EA (1) EA004933B1 (de)
ES (1) ES2223008T3 (de)
PT (1) PT1315730E (de)
SI (1) SI1315730T1 (de)
TR (1) TR200402519T4 (de)
WO (1) WO2002018385A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1184384A1 (de) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyridin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
EP1340759A1 (de) 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyrimidin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
AU2005206557A1 (en) 2004-01-22 2005-08-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
FR2928070A1 (fr) * 2008-02-27 2009-09-04 Sumitomo Chemical Co Composition agricole, utilisation d'un compose pour sa production et procede pour matriser ou prevenir les maladies des plantes.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
SG10201403138WA (en) * 2009-07-02 2014-08-28 Sanofi Sa Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof and pharmaceutical use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6098753A (en) * 1998-06-05 2000-08-08 Pratt & Whitney Canada Corp. System for delivering pressurized lubricant fluids to an interior of a rotating hollow shaft
TWI241298B (en) * 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
EP1184384A1 (de) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyridin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate

Also Published As

Publication number Publication date
DK1315730T3 (da) 2004-10-25
EP1184384A1 (de) 2002-03-06
JP2004507545A (ja) 2004-03-11
CA2419875A1 (en) 2002-03-07
SI1315730T1 (en) 2005-02-28
CA2419875C (en) 2010-06-15
EA200300150A1 (ru) 2003-08-28
KR100775192B1 (ko) 2007-11-12
CN1451006A (zh) 2003-10-22
ATE270293T1 (de) 2004-07-15
DE60104130T2 (de) 2005-03-10
EP1315730A1 (de) 2003-06-04
AU2002212248B2 (en) 2007-01-04
PT1315730E (pt) 2004-10-29
TR200402519T4 (tr) 2004-12-21
KR20030029892A (ko) 2003-04-16
AU1224802A (en) 2002-03-13
EP1315730B1 (de) 2004-06-30
WO2002018385A1 (en) 2002-03-07
ES2223008T3 (es) 2005-02-16
EA004933B1 (ru) 2004-10-28
US7067521B2 (en) 2006-06-27
US7608624B2 (en) 2009-10-27
CN1247584C (zh) 2006-03-29
JP4958379B2 (ja) 2012-06-20
US20040044010A1 (en) 2004-03-04
US20060148825A1 (en) 2006-07-06
AR030588A1 (es) 2003-08-27

Similar Documents

Publication Publication Date Title
ATE370931T1 (de) Heterozyklische verbindungen und ihre verwendungen
ATE318603T1 (de) Pyrrolotriazin kinasehemmer
ATE375987T1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
IT1308096B1 (it) Convertiplano
NO20025154L (no) Imidazopyrimidinderivater og triazolpyrimidinderivater
DE60009741D1 (de) Zusammenklappbare lagerpalette
CY2007002I1 (el) Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης
NO20020304D0 (no) Konserverte farmasöytiske preparater
DK1175408T3 (da) Pyrimidinonforbindelser
ATE229955T1 (de) Substituierte 1,8-naphthyridin-4(1h)-one als phosphodiesterase 4-inhibitoren
IT1310042B1 (it) Filtro senza spazio morto
DE60302221D1 (de) Heteroaryl substituierte 2-pyridinyl und 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-onderivate
DE60205921D1 (de) SUBSTITUIERTE 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDOç1,2-A!PYRIMIDIN-4-ON- UND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO-ç1,2-A!PYRIMIDIN-5(1H)ONDERIVATE
ZA200109338B (en) Substituted polycyclic aryl and heteroaryl uracils as anti-coagulative agents.
DE60104130D1 (de) 1-(alkyl), 1-[(heteroaryl)alkyl] und 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-onderivate
DK1480981T3 (da) 1-(Alkyl)-, 1-(heteroaryl)alkyl- og 1-[(aryl)alkyl]-7-(pyrimidin-4-yl) imidazo[1,2a]pyrimidin-5(1H)-onderivater
NZ513732A (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists
MXPA03004136A (es) Derivados de pirimidina y su uso como ligandos del receptor de neuropeptido y (npy).
ATA161299A (de) Holster
GB0120818D0 (en) Heterocyclic compounds
DE60135797D1 (de) Kunstleder
NO20025659L (no) Heterocykliske forbindelser
DE50003014D1 (de) N-substituierte perhydrodiazine
GB0021315D0 (en) Heterocyclic compounds and intermediates thereof
IT1305338B1 (it) Elementi passivi in volumi chiusi, per altoparlanti

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1315730

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE